Mena FN

Urea Cycle Disorders Treatment Market Projected To Reach $1.62 Billion With 4.2% CAGR By 2029

(MENAFN- EIN Presswire) EINPresswire/ -- What Is The Expected Cagr For The Urea Cycle Disorders Treatment Market Through 2025? In recent times, the market size for treatment of urea cycle disorders ...
Seeking Alpha

Acer Therapeutics Announces Presentation of HCP Urea Cycle Disorder Treatment Preference Data at the Society for Inherited Metabolic Disorders Annual Meeting and Provides ...

OLPRUVA™ preliminary launch activities progressing; building out commercial and medical affairs teams to support U.S. launch in Q2 2023, with drug availability anticipated by early July 2023 Poster ...
WDAF-TV

Relief Therapeutics Announces Survey Results Identifying Preferred Urea Cycle Disorder Treatment Attributes Presented by Collaboration Partner at SIMD 2023

Acer Therapeutics reports data from a survey of UCD healthcare providers show taste and odor are the most important attributes when considering treatment options and adherence GENEVA, SWITZERLAND / ...
Nasdaq

Acer Therapeutics and Relief Therapeutics Announce Submission of a New Drug Application to the U.S. FDA for ACER-001 for Treatment of Urea Cycle Disorders

NEWTON, Mass. and GENEVA, Aug. 09, 2021 (GLOBE NEWSWIRE) -- Acer Therapeutics Inc. (Nasdaq: ACER) (“Acer”), a pharmaceutical company focused on the acquisition, development and commercialization of ...